Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
N-acetylcys..
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
Summary
All studies
Mortality
Hospitalization
Serious outcomes
Recovery
RCTs
RCT mortality
All outcomes

Feedback
Home   COVID-19 treatment studies for Ensovibep  COVID-19 treatment studies for Ensovibep  C19 studies: Ensovibep  Ensovibep   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) N-acetylcys.. (meta)
Bromhexine (meta) Nigella Sativa (meta)
Budesonide (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Povidone-Iod.. (meta)
Conv. Plasma (meta) Probiotics (meta)
Curcumin (meta) Proxalutamide (meta)
Ensovibep (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychlor.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
Outcomes in COVID-19 ensovibep studies
Outcomes in ensovibep studies. Ensovibep requires IV infusion, but may be less variant dependent than monoclonal antibodies.
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ All studies 45% 2 400 Improvement, Studies, Patients Relative Risk Mortality 89% 1 400 Hospitalization 87% 1 400 RCTs 45% 2 400 Early 89% 1 400 Late 0% 1 0 Ensovibep for COVID-19 c19early.com/ev Jan 16, 2022 Favors ensovibep Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Novartis (RCT) 89% 0.11 [0.01-2.27] death 0/301 2/99 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.15 Early treatment 89% 0.11 [0.01-2.27] 0/301 2/99 89% improvement ACTIV-3 (RCT) 0% 1.00 [0.50-2.00] recovery n/a n/a FUTILITY, PENDING​1 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.50-2.00] 0% improvement All studies 45% 0.55 [0.08-3.76] 0/301 2/99 45% improvement 2 ensovibep COVID-19 studies c19early.com/ev Jan 16, 2022 Tau​2 = 1.18, I​2 = 48.4%, p = 0.56 Effect extraction pre-specified 1 FUTILITY: terminated for futility, results pending Favors ensovibep Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Novartis (RCT) 89% 0.11 [0.01-2.27] 0/301 2/99 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.15 Early treatment 89% 0.11 [0.01-2.27] 0/301 2/99 89% improvement All studies 89% 0.11 [0.01-2.27] 0/301 2/99 89% improvement 1 ensovibep COVID-19 mortality result c19early.com/ev Jan 16, 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.15 Favors ensovibep Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Novartis (RCT) 87% 0.13 [0.03-0.67] hosp. 2/301 5/99 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.014 Early treatment 87% 0.13 [0.03-0.67] 2/301 5/99 87% improvement All studies 87% 0.13 [0.03-0.67] 2/301 5/99 87% improvement 1 ensovibep COVID-19 hospitalization result c19early.com/ev Jan 16, 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.014 Favors ensovibep Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Novartis (RCT) 89% 0.11 [0.01-2.27] death 0/301 2/99 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.15 Early treatment 89% 0.11 [0.01-2.27] 0/301 2/99 89% improvement All studies 89% 0.11 [0.01-2.27] 0/301 2/99 89% improvement 1 ensovibep COVID-19 serious outcomes c19early.com/ev Jan 16, 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.15 Effect extraction pre-specified Favors ensovibep Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ACTIV-3 (RCT) 0% 1.00 [0.50-2.00] recovery n/a n/a FUTILITY, PENDING​1 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.50-2.00] 0% improvement All studies 0% 1.00 [0.50-2.00] 0% improvement 1 ensovibep COVID-19 recovery result c19early.com/ev Jan 16, 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 1. 1 FUTILITY: terminated for futility, results pending Favors ensovibep Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Novartis (RCT) 89% 0.11 [0.01-2.27] death 0/301 2/99 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.15 Early treatment 89% 0.11 [0.01-2.27] 0/301 2/99 89% improvement ACTIV-3 (RCT) 0% 1.00 [0.50-2.00] recovery n/a n/a FUTILITY, PENDING​1 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.50-2.00] 0% improvement All studies 45% 0.55 [0.08-3.76] 0/301 2/99 45% improvement 2 ensovibep COVID-19 Randomized Controlled Trials c19early.com/ev Jan 16, 2022 Tau​2 = 1.18, I​2 = 48.4%, p = 0.56 Effect extraction pre-specified 1 FUTILITY: terminated for futility, results pending Favors ensovibep Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Novartis (RCT) 89% 0.11 [0.01-2.27] 0/301 2/99 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.15 Early treatment 89% 0.11 [0.01-2.27] 0/301 2/99 89% improvement All studies 89% 0.11 [0.01-2.27] 0/301 2/99 89% improvement 1 ensovibep COVID-19 RCT mortality result c19early.com/ev Jan 16, 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.15 Favors ensovibep Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Novartis (RCT) 89% 0.11 [0.01-2.27] death 0/301 2/99 Improvement, RR [CI] Treatment Control Novartis (RCT) 87% 0.13 [0.03-0.67] hosp. 2/301 5/99 Novartis (RCT) 78% 0.22 [0.06-0.76] hosp./ER 4/301 6/99 ACTIV-3 (RCT) 0% 1.00 [0.50-2.00] recovery n/a n/a FUTILITY, PENDING​1 ensovibep COVID-19 outcomes c19early.com/ev Jan 16, 2022 1 FUTILITY: terminated for futility, results pending Favors ensovibep Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. WCH and FLCCC provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit